{
    "root": "ed78fbb6-5691-44be-859d-16b30f768614",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "Human Prescription Drug Label",
    "name": {
        "text": "Aripiprazole"
    },
    "value": "20250219",
    "ingredients": [
        {
            "name": "ARIPIPRAZOLE",
            "code": "82VFR53I78"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "CROSPOVIDONE",
            "code": "68401960MK"
        },
        {
            "name": "ASPARTAME",
            "code": "Z0H242BBR1"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "CALCIUM STEARATE",
            "code": "776XM7047L"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        }
    ],
    "indications": "aripiprazole orally disintegrating tablets , usp indicated treatment : •schizophrenia [ ( 14.1 ) ] • irritability associated autistic disorder [ ( 14.4 ) ] • treatment tourette ’ disorder [ ( 14.5 ) ]",
    "contraindications": "initial dose recommended dose maximum dose schizophrenia – adults ( 2.1 ) 10 15 mg /day 10 15 mg /day 30 mg /day schizophrenia – adolescents ( 2.1 ) 2 mg /day 10 mg /day 30 mg /day irritability associated autistic disorder – pediatric patients ( 2.4 ) 2 mg/day 5 10 mg/day 15 mg/day tourette ’ disorder – ( 2.5 ) patients < 50 kg 2 mg/day 5 mg/day 10 mg/day patients ≥ 50 kg 2 mg/day 10 mg/day 20 mg/day •oral formulations : administer daily without regard meals ( 2 ) •known cyp2d6 poor metabolizers : half usual dose ( 2.7 )",
    "warningsAndPrecautions": null,
    "adverseReactions": "aripiprazole orally disintegrating tablets contraindicated patients history hypersensitivity reaction aripiprazole . ranged pruritus/urticaria anaphylaxis [ ( 6.2 ) ] .",
    "indications_original": "Aripiprazole Orally Disintegrating Tablets, USP are indicated for the treatment of: •Schizophrenia [see Clinical Studies (14.1)]\n                  \n                  • Irritability Associated with Autistic Disorder [see Clinical Studies (14.4)]\n                     • Treatment of Tourette’s Disorder [see Clinical Studies (14.5)]",
    "contraindications_original": "Initial            Dose Recommended Dose Maximum Dose Schizophrenia – adults (2.1) 10 to 15 mg /day 10 to 15 mg /day 30 mg /day Schizophrenia – adolescents (2.1) 2 mg /day 10 mg /day 30 mg /day Irritability associated with autistic disorder – pediatric patients (2.4) 2 mg/day 5 to 10 mg/day 15 mg/day Tourette’s disorder – (2.5) Patients < 50 kg 2 mg/day 5 mg/day 10 mg/day Patients ≥ 50 kg 2 mg/day 10 mg/day 20 mg/day •Oral formulations: Administer once daily without regard to meals (2) •Known CYP2D6 poor metabolizers: Half of the usual dose (2.7)",
    "adverseReactions_original": "Aripiprazole orally disintegrating tablets are contraindicated in patients with a history of a hypersensitivity reaction to aripiprazole. Reactions have ranged from pruritus/urticaria to anaphylaxis [see Adverse Reactions(6.2)]."
}